A detailed history of Royal Bank Of Canada transactions in Pulmonx Corp stock. As of the latest transaction made, Royal Bank Of Canada holds 5,540 shares of LUNG stock, worth $35,123. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,540
Previous 3,647 51.91%
Holding current value
$35,123
Previous $23,000 95.65%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.59 - $8.58 $10,581 - $16,241
1,893 Added 51.91%
5,540 $45,000
Q2 2024

Aug 14, 2024

BUY
$5.77 - $9.82 $3,790 - $6,451
657 Added 21.97%
3,647 $23,000
Q1 2024

Nov 05, 2024

SELL
$8.71 - $14.65 $5,722 - $9,625
-657 Reduced 18.01%
2,990 $27,000
Q1 2024

May 15, 2024

SELL
$8.71 - $14.65 $92,787 - $156,066
-10,653 Reduced 78.08%
2,990 $27,000
Q4 2023

Feb 14, 2024

BUY
$7.89 - $13.14 $71,412 - $118,930
9,051 Added 197.1%
13,643 $173,000
Q3 2023

Nov 14, 2023

BUY
$9.88 - $14.0 $14,820 - $21,000
1,500 Added 48.51%
4,592 $47,000
Q2 2023

Aug 14, 2023

BUY
$10.78 - $13.65 $12,666 - $16,038
1,175 Added 61.29%
3,092 $40,000
Q1 2023

May 15, 2023

SELL
$7.49 - $12.54 $32,064 - $53,683
-4,281 Reduced 69.07%
1,917 $21,000
Q4 2022

Feb 14, 2023

BUY
$4.92 - $17.35 $28,442 - $100,300
5,781 Added 1386.33%
6,198 $52,000
Q3 2022

Nov 14, 2022

BUY
$15.35 - $23.99 $3,453 - $5,397
225 Added 117.19%
417 $7,000
Q2 2022

Aug 15, 2022

SELL
$14.0 - $27.95 $19,782 - $39,493
-1,413 Reduced 88.04%
192 $3,000
Q1 2022

May 16, 2022

SELL
$21.13 - $35.65 $82,660 - $139,462
-3,912 Reduced 70.91%
1,605 $40,000
Q4 2021

Feb 14, 2022

BUY
$29.72 - $45.1 $87,436 - $132,684
2,942 Added 114.25%
5,517 $177,000
Q3 2021

Nov 15, 2021

BUY
$35.98 - $44.48 $26,481 - $32,737
736 Added 40.02%
2,575 $93,000
Q2 2021

Aug 16, 2021

BUY
$37.61 - $48.0 $69,164 - $88,272
1,839 New
1,839 $81,000

Others Institutions Holding LUNG

About Pulmonx Corp


  • Ticker LUNG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 37,268,400
  • Market Cap $236M
  • Description
  • Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...
More about LUNG
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.